TipRanks
West Pharmaceutical Services, Inc. (WST)
NYSE:WST
US Market
Want to see WST full AI Analyst Report?

West Pharmaceutical Services (WST) Segment Operating Income Breakdown

939 Followers

Segment Operating Income Breakdown

Breaks down profitability by segment to show which businesses generate the most operating income and margins. This helps identify high-margin drivers versus cost-heavy areas, assess pricing power and operational efficiency, and prioritize where capital allocation or cost control will most affect earnings and valuation.
Proprietary Products’ operating income has rebounded from its early‑2024 trough to near‑peak levels by Q1’26, reflecting HVP/GLP‑1 mix, biologics/NovaPure momentum and Annex‑1 conversion that management cited as key drivers of margin expansion and upgraded FY26 guidance. West Vantage remains small and lumpy — Dublin ramp and contract timing have depressed near‑term profitability and create H2 variability, and a ~$40M CGM roll‑off adds back‑half headwind. The $1B buyback and raised guidance signal confidence but watch ramp timing and contract exits for sustainability.
Date
Proprietary Products
West Vantage
Jun 30, 2026
$211.90M$12.90M
Mar 31, 2026
$189.20M$15.60M
Dec 31, 2025
$189.70M$9.80M
Sep 30, 2025
$175.20M$22.30M
Jun 30, 2025
$161.70M$17.80M
Mar 31, 2025
$130.60M$13.50M
Dec 31, 2024
$162.30M$16.20M
Sep 30, 2024
$158.20M$21.80M
Jun 30, 2024
$131.00M$17.20M
Mar 31, 2024
$126.30M$17.10M